Advertisement

Cannabis Legalization Does Not Influence Patient Compliance with Opioid Therapy

Published:November 10, 2018DOI:https://doi.org/10.1016/j.amjmed.2018.11.002

      Abstract

      Background

      Prescription opioid use and opioid related deaths continue to increase nationwide. Several states have adopted legislation allowing for recreational use of cannabis. Little is known about how recreational cannabis laws impact compliance in chronic pain patients who have been prescribed opioid therapy. The goals of this study were to (1) retrospectively assess the effect of cannabis use on compliance with opioid therapy in a high-risk patient population and (2) determine the impact of legalization of recreational cannabis on patients prescribed therapeutic opioids.

      Methods

      We conducted a retrospective cohort study on results from a “high-risk” urine drug testing panel. Results from 1 year before and 1 year after initiation of recreational cannabis legislation were analyzed. This testing panel included qualitative assays for cannabinoids and 9 other common drugs of abuse in addition to a quantitative LC-MS/MS assay for 23 different opioids and metabolites. Opioid compliance was assigned by reviewing pathologists’ interpretations.

      Results

      In the pre-legalization period, 1776 panels were performed, and in the post-legalization, 1648 panels were performed. An increase (6%) in the rate of positive cannabinoids screening results was observed after legalization of recreational cannabis; however, the overall compliance rate was consistent.

      Conclusions

      The results of this study suggest that legalization of recreational cannabis does not affect compliance rate in patients treated with opioid therapy for chronic pain.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Nuckols TK
        • Anderson L
        • Popescu I
        • et al.
        Opioid prescribing: a systematic review and critical appraisal of guidelines for chronic pain.
        Ann Intern Med. 2014; 160: 38-47
        • Manchikanti L
        • Kaye AM
        • Knezevic NN
        • et al.
        Responsible, safe, and effective prescription of opioids for chronic non-cancer pain: American Society of Interventional Pain Physicians (ASIPP) guidelines.
        Pain Physician. 2017; 20: S3-92
        • Daubresse M
        • Chang HY
        • Yu Y
        • et al.
        Ambulatory diagnosis and treatment of nonmalignant pain in the United States, 2000-2010.
        Med Care. 2013; 51: 870-878
        • Rudd R
        • Seth P
        • David F
        • Scholl L
        Increases in drug and opioid-involved overdose deaths—United States, 2010-2015.
        Morb Mortal Wkly Rep. 2016; : 1445-1452
        • Dowell D
        • Haegerich TM
        • Chou R
        CDC guideline for prescribing opioids for chronic pain—United States, 2016.
        JAMA. 2016; 315: 1624-1645
        • Katz N
        • Fanciullo GJ
        Role of urine toxicology testing in the management of chronic opioid therapy.
        Clin J Pain. 2002; 18: S76-S82
        • Savage SR
        Management of opioid medications in patients with chronic pain and risk of substance misuse.
        Curr Psychiatry Rep. 2009; 11: 377-384
        • Kaye AD
        • Jones MR
        • Kaye AM
        • et al.
        Prescription opioid abuse in chronic pain: an updated review of opioid abuse predictors and strategies to curb opioid abuse: part 1.
        Pain Physician. 2017; 20: S93-S109
        • Cerdá M
        • Wall M
        • Keyes KM
        • Galea S
        • Hasin D
        Medical marijuana laws in 50 states: investigating the relationship between state legalization of medical marijuana and marijuana use, abuse and dependence.
        Drug Alcohol Depend. 2012; 120: 22-27
      1. Washington Secretary of State. Initiative measure no. 502. Available at: http://www.sos.wa.gov/elections/initiatives/text/i502.pdf. Accessed September 14, 2017.

        • Roffman R
        Legalization of cannabis in Washington State: how is it going?.
        Addiction. 2016; 111: 1139-1140
        • Jensen B
        • Chen J
        • Furnish T
        • Wallace M
        Medical marijuana and chronic pain: a review of basic science and clinical evidence.
        Curr Pain Headache Rep. 2015; 19: 50
        • Stith SS
        • Vigil JM
        • Adams IM
        • Reeve AP
        Effects of legal access to cannabis on scheduled II-V drug prescriptions.
        J Am Med Dir Assoc. 2018; 19: 59-64
        • Lucas P
        Rationale for cannabis-based interventions in the opioid overdose crisis.
        Harm Reduct J. 2017; 14: 58
        • Pesce A
        • West C
        • Rosenthal M
        • et al.
        Marijuana correlates with use of other illicit drugs in a pain patient population.
        Pain Physician. 2010; 13: 283-287
        • Webster LR
        • Webster RM
        Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the opioid risk tool.
        Pain Med. 2005; 6: 432-442
        • Dickerson JA
        • Laha TJ
        • Pagano MB
        • O'Donnell BR
        • Hoofnagle AN
        Improved detection of opioid use in chronic pain patients through monitoring of opioid glucuronides in urine.
        J Anal Toxicol. 2012; 36: 541-547
        • Hasin DS
        • Sarvet AL
        • Cerdá M
        • et al.
        US adult illicit cannabis use, cannabis use disorder, and medical marijuana laws: 1991-1992 to 2012-2013.
        JAMA Psychiatry. 2017; 74: 579-588
        • Hall W
        • Lynskey M
        Evaluating the public health impacts of legalizing recreational cannabis use in the United States.
        Addiction. 2016; 111: 1764-1773
        • Bawor M
        • Dennis BB
        • Varenbut M
        • et al.
        Sex differences in substance use, health, and social functioning among opioid users receiving methadone treatment: a multicenter cohort study.
        Biol Sex Differ. 2015; 6: 21
        • Cuttler C
        • Mischley LK
        • Sexton M
        Sex differences in cannabis use and effects: a cross-sectional survey of cannabis users.
        Cannabis Cannabinoid Res. 2016; 1: 166-175
        • Muro AIR
        Age, sex and personality in early cannabis use.
        Eur Psychiatry J Assoc Eur Psychiatr. 2015; 30: 469-473
        • Pergam SA
        • Woodfield MC
        • Lee CM
        • et al
        Cannabis use among patients at a comprehensive cancer center in a state with legalized medicinal and recreational use..
        Cancer. 2017; 123: 4488-4497
        • Rosner F
        Patient noncompliance.
        Mt Sinai J Med. 2006; 73: 553
        • Bootman JL
        • Harrison DL
        • Cox E
        The health care cost of drug-related morbidity and mortality in nursing facilities.
        Arch Intern Med. 1997; 157: 2089-2096
        • Bachhuber MA
        • Saloner B
        • Cunningham CO
        • Barry CL
        Medical cannabis laws and opioid analgesic overdose mortality in the united states, 1999-2010.
        JAMA Intern Med. 2014; 174: 1668-1673
        • Livingston MD
        • Barnett TE
        • Delcher C
        • Wagenaar AC
        Recreational cannabis legalization and opioid-related deaths in Colorado.
        Am J Public Health. 2017; 107: 1827-1829
        • Boehnke KF
        • Litinas E
        • Clauw DJ.
        Medical cannabis use is associated with decreased opiate medication use in a retrospective cross-sectional survey of patients with chronic pain.
        J Pain. 2016; 17: 739-744